INESSS in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section
June 23, 2026
INESSS (the Institut national d’excellence en santé et en services sociaux) in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section!
Denosumab is currently available only through the exceptional patient measure administered by the Régie de l’assurance maladie du Québec (RAMQ), resulting in an administrative burden.
Clinicians have noted inequities in access to denosumab for the treatment of osteoporosis between men and women, a distinction that is not supported by any scientific justification. There is therefore a need to standardize practice across Quebec and address the observed inequalities in access to treatment.
These changes are expected to meaningfully support both patients and the health care system.
Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones
July 7, 2026
Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]
INESSS in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section
June 23, 2026
Latest News INESSS in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section June 23, 2026 INESSS (the Institut national d’excellence en […]
Health Canada Approves of DENOZA™, a Denosumab Biosimilar
May 5, 2026
Latest News Health Canada Approves of DENOZA™, a Denosumab Biosimilar May 5, 2026 Apotex Inc., a Canadian based global pharmaceutical company announced that Health Canada has approved DENOZA™ (denosumab injection), […]
